COVID-19 Impact on Global Neuromuscular Blocking Agent (NMBA) Market Insights, Forecast to 2026
Neuromuscular Blocking Agent (NMBA) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuromuscular Blocking Agent (NMBA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Neuromuscular Blocking Agent (NMBA) market is segmented into
The Neuromuscular Blocking Agent (NMBA) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuromuscular Blocking Agent (NMBA) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neuromuscular Blocking Agent (NMBA) Market Share Analysis
Neuromuscular Blocking Agent (NMBA) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuromuscular Blocking Agent (NMBA) business, the date to enter into the Neuromuscular Blocking Agent (NMBA) market, Neuromuscular Blocking Agent (NMBA) product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Neuromuscular Blocking Agent (NMBA) market is segmented into
- Depolarizing
- Non-depolarizing
- Hospital
- Clinic
- Pharmacy
- Others
The Neuromuscular Blocking Agent (NMBA) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Neuromuscular Blocking Agent (NMBA) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Neuromuscular Blocking Agent (NMBA) Market Share Analysis
Neuromuscular Blocking Agent (NMBA) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Neuromuscular Blocking Agent (NMBA) business, the date to enter into the Neuromuscular Blocking Agent (NMBA) market, Neuromuscular Blocking Agent (NMBA) product introduction, recent developments, etc.
The major vendors covered:
- AbbVie
- GlaxoSmithKline
- Pfizer
- Hengrui Pharmaceutical
- Abbott Laboratories
- Fresenius Kabi
- Sandoz
- Somerset Therapeutics
- Guike Pharmaceutical
- Shanghai Pharmaceuticals
- Themis Medicare
- Nanjing King-Friend
1 STUDY COVERAGE
1.1 Neuromuscular Blocking Agent (NMBA) Product Introduction
1.2 Market Segments
1.3 Key Neuromuscular Blocking Agent (NMBA) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type
1.4.2 Depolarizing
1.4.3 Non-depolarizing
1.5 Market by Application
1.5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Pharmacy
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Neuromuscular Blocking Agent (NMBA) Industry Impact
1.6.1 How the Covid-19 is Affecting the Neuromuscular Blocking Agent (NMBA) Industry
1.6.1.1 Neuromuscular Blocking Agent (NMBA) Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Neuromuscular Blocking Agent (NMBA) Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Neuromuscular Blocking Agent (NMBA) Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
2.1.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2015-2026
2.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2015-2026
2.2 Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2020 Versus 2026
2.2.1 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL NEUROMUSCULAR BLOCKING AGENT (NMBA) COMPETITOR LANDSCAPE BY PLAYERS
3.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers
3.1.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers (2015-2020)
3.1.2 Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2015-2020)
3.2 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers
3.2.1 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2015-2020)
3.2.2 Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuromuscular Blocking Agent (NMBA) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuromuscular Blocking Agent (NMBA) Revenue in 2019
3.2.5 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neuromuscular Blocking Agent (NMBA) Price by Manufacturers
3.4 Neuromuscular Blocking Agent (NMBA) Manufacturing Base Distribution, Product Types
3.4.1 Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
3.4.3 Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Type (2015-2020)
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2015-2020)
4.1.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type (2021-2026)
4.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Type (2021-2026)
4.2.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Application (2015-2020)
5.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020)
5.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2015-2020)
5.1.3 Neuromuscular Blocking Agent (NMBA) Price by Application (2015-2020)
5.2 Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Application (2021-2026)
5.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuromuscular Blocking Agent (NMBA) Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Neuromuscular Blocking Agent (NMBA) by Country
6.1.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Country
6.1.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
6.3 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
7 EUROPE
7.1 Europe Neuromuscular Blocking Agent (NMBA) by Country
7.1.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country
7.1.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
7.3 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Region
8.1.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region
8.1.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
8.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Neuromuscular Blocking Agent (NMBA) by Country
9.1.1 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country
9.1.2 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
9.3 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Country
10.1.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country
10.1.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
10.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
11.1.5 AbbVie Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Description, Business Overview and Total Revenue
11.2.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Products Offered
11.2.5 GlaxoSmithKline Recent Development
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description, Business Overview and Total Revenue
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Products Offered
11.3.5 Pfizer Recent Development
11.4 Hengrui Pharmaceutical
11.4.1 Hengrui Pharmaceutical Corporation Information
11.4.2 Hengrui Pharmaceutical Description, Business Overview and Total Revenue
11.4.3 Hengrui Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
11.4.5 Hengrui Pharmaceutical Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Corporation Information
11.5.2 Abbott Laboratories Description, Business Overview and Total Revenue
11.5.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Products Offered
11.5.5 Abbott Laboratories Recent Development
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Corporation Information
11.6.2 Fresenius Kabi Description, Business Overview and Total Revenue
11.6.3 Fresenius Kabi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Products Offered
11.6.5 Fresenius Kabi Recent Development
11.7 Sandoz
11.7.1 Sandoz Corporation Information
11.7.2 Sandoz Description, Business Overview and Total Revenue
11.7.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Products Offered
11.7.5 Sandoz Recent Development
11.8 Somerset Therapeutics
11.8.1 Somerset Therapeutics Corporation Information
11.8.2 Somerset Therapeutics Description, Business Overview and Total Revenue
11.8.3 Somerset Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Products Offered
11.8.5 Somerset Therapeutics Recent Development
11.9 Guike Pharmaceutical
11.9.1 Guike Pharmaceutical Corporation Information
11.9.2 Guike Pharmaceutical Description, Business Overview and Total Revenue
11.9.3 Guike Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
11.9.5 Guike Pharmaceutical Recent Development
11.10 Shanghai Pharmaceuticals
11.10.1 Shanghai Pharmaceuticals Corporation Information
11.10.2 Shanghai Pharmaceuticals Description, Business Overview and Total Revenue
11.10.3 Shanghai Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Products Offered
11.10.5 Shanghai Pharmaceuticals Recent Development
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
11.1.5 AbbVie Recent Development
11.12 Nanjing King-Friend
11.12.1 Nanjing King-Friend Corporation Information
11.12.2 Nanjing King-Friend Description, Business Overview and Total Revenue
11.12.3 Nanjing King-Friend Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Nanjing King-Friend Products Offered
11.12.5 Nanjing King-Friend Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Region
12.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions 2021-2026
12.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions 2021-2026
12.2 North America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.2.1 North America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.2.2 North America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.2.3 North America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.3.1 Europe: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.3.2 Europe: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.3.3 Europe: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Region (2021-2026)
12.5 Latin America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.5.1 Latin America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.5.2 Latin America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.5.3 Latin America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neuromuscular Blocking Agent (NMBA) Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Neuromuscular Blocking Agent (NMBA) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Neuromuscular Blocking Agent (NMBA) Product Introduction
1.2 Market Segments
1.3 Key Neuromuscular Blocking Agent (NMBA) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type
1.4.2 Depolarizing
1.4.3 Non-depolarizing
1.5 Market by Application
1.5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Pharmacy
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Neuromuscular Blocking Agent (NMBA) Industry Impact
1.6.1 How the Covid-19 is Affecting the Neuromuscular Blocking Agent (NMBA) Industry
1.6.1.1 Neuromuscular Blocking Agent (NMBA) Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Neuromuscular Blocking Agent (NMBA) Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Neuromuscular Blocking Agent (NMBA) Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Neuromuscular Blocking Agent (NMBA) Market Size Estimates and Forecasts
2.1.1 Global Neuromuscular Blocking Agent (NMBA) Revenue 2015-2026
2.1.2 Global Neuromuscular Blocking Agent (NMBA) Sales 2015-2026
2.2 Neuromuscular Blocking Agent (NMBA) Market Size by Region: 2020 Versus 2026
2.2.1 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neuromuscular Blocking Agent (NMBA) Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL NEUROMUSCULAR BLOCKING AGENT (NMBA) COMPETITOR LANDSCAPE BY PLAYERS
3.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers
3.1.1 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers (2015-2020)
3.1.2 Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturers (2015-2020)
3.2 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers
3.2.1 Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2015-2020)
3.2.2 Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuromuscular Blocking Agent (NMBA) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuromuscular Blocking Agent (NMBA) Revenue in 2019
3.2.5 Global Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neuromuscular Blocking Agent (NMBA) Price by Manufacturers
3.4 Neuromuscular Blocking Agent (NMBA) Manufacturing Base Distribution, Product Types
3.4.1 Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
3.4.3 Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Type (2015-2020)
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2015-2020)
4.1.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Type (2021-2026)
4.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Type (2021-2026)
4.2.3 Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuromuscular Blocking Agent (NMBA) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Application (2015-2020)
5.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020)
5.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2015-2020)
5.1.3 Neuromuscular Blocking Agent (NMBA) Price by Application (2015-2020)
5.2 Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Application (2021-2026)
5.2.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuromuscular Blocking Agent (NMBA) Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Neuromuscular Blocking Agent (NMBA) by Country
6.1.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Country
6.1.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
6.3 North America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
7 EUROPE
7.1 Europe Neuromuscular Blocking Agent (NMBA) by Country
7.1.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Country
7.1.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
7.3 Europe Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) by Region
8.1.1 Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region
8.1.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
8.3 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Neuromuscular Blocking Agent (NMBA) by Country
9.1.1 Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country
9.1.2 Latin America Neuromuscular Blocking Agent (NMBA) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
9.3 Central & South America Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) by Country
10.1.1 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country
10.1.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Type
10.3 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
11.1.5 AbbVie Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Description, Business Overview and Total Revenue
11.2.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Products Offered
11.2.5 GlaxoSmithKline Recent Development
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description, Business Overview and Total Revenue
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Products Offered
11.3.5 Pfizer Recent Development
11.4 Hengrui Pharmaceutical
11.4.1 Hengrui Pharmaceutical Corporation Information
11.4.2 Hengrui Pharmaceutical Description, Business Overview and Total Revenue
11.4.3 Hengrui Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
11.4.5 Hengrui Pharmaceutical Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Corporation Information
11.5.2 Abbott Laboratories Description, Business Overview and Total Revenue
11.5.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Products Offered
11.5.5 Abbott Laboratories Recent Development
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Corporation Information
11.6.2 Fresenius Kabi Description, Business Overview and Total Revenue
11.6.3 Fresenius Kabi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Products Offered
11.6.5 Fresenius Kabi Recent Development
11.7 Sandoz
11.7.1 Sandoz Corporation Information
11.7.2 Sandoz Description, Business Overview and Total Revenue
11.7.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Products Offered
11.7.5 Sandoz Recent Development
11.8 Somerset Therapeutics
11.8.1 Somerset Therapeutics Corporation Information
11.8.2 Somerset Therapeutics Description, Business Overview and Total Revenue
11.8.3 Somerset Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Products Offered
11.8.5 Somerset Therapeutics Recent Development
11.9 Guike Pharmaceutical
11.9.1 Guike Pharmaceutical Corporation Information
11.9.2 Guike Pharmaceutical Description, Business Overview and Total Revenue
11.9.3 Guike Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Products Offered
11.9.5 Guike Pharmaceutical Recent Development
11.10 Shanghai Pharmaceuticals
11.10.1 Shanghai Pharmaceuticals Corporation Information
11.10.2 Shanghai Pharmaceuticals Description, Business Overview and Total Revenue
11.10.3 Shanghai Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Products Offered
11.10.5 Shanghai Pharmaceuticals Recent Development
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Products Offered
11.1.5 AbbVie Recent Development
11.12 Nanjing King-Friend
11.12.1 Nanjing King-Friend Corporation Information
11.12.2 Nanjing King-Friend Description, Business Overview and Total Revenue
11.12.3 Nanjing King-Friend Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Nanjing King-Friend Products Offered
11.12.5 Nanjing King-Friend Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Neuromuscular Blocking Agent (NMBA) Market Estimates and Projections by Region
12.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions 2021-2026
12.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions 2021-2026
12.2 North America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.2.1 North America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.2.2 North America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.2.3 North America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.3.1 Europe: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.3.2 Europe: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.3.3 Europe: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Region (2021-2026)
12.5 Latin America Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.5.1 Latin America: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.5.2 Latin America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.5.3 Latin America: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Neuromuscular Blocking Agent (NMBA) Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Neuromuscular Blocking Agent (NMBA) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Neuromuscular Blocking Agent (NMBA) Market Segments
Table 2. Ranking of Global Top Neuromuscular Blocking Agent (NMBA) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of Depolarizing
Table 5. Major Manufacturers of Non-depolarizing
Table 6. COVID-19 Impact Global Market: (Four Neuromuscular Blocking Agent (NMBA) Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Neuromuscular Blocking Agent (NMBA) Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Neuromuscular Blocking Agent (NMBA) Players to Combat Covid-19 Impact
Table 11. Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application 2020-2026 (MT)
Table 12. Global Neuromuscular Blocking Agent (NMBA) Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 13. Global Neuromuscular Blocking Agent (NMBA) Sales by Regions 2015-2020 (MT)
Table 14. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Regions (2015-2020)
Table 15. Global Neuromuscular Blocking Agent (NMBA) Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers (2015-2020) (MT)
Table 17. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturers (2015-2020)
Table 18. Global Neuromuscular Blocking Agent (NMBA) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Neuromuscular Blocking Agent (NMBA) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromuscular Blocking Agent (NMBA) as of 2019)
Table 20. Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Neuromuscular Blocking Agent (NMBA) Price (2015-2020) (USD/MT)
Table 23. Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
Table 25. Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 28. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Type (2015-2020)
Table 29. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Type (2015-2020)
Table 31. Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 33. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Application (2015-2020)
Table 34. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 35. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 36. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 38. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 39. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 40. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 41. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 42. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 43. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 44. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 46. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 47. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 48. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 49. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2015-2020) (MT)
Table 51. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 55. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 57. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 58. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 59. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 62. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 63. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 64. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 65. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 67. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 71. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 73. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 74. AbbVie Corporation Information
Table 75. AbbVie Description and Major Businesses
Table 76. AbbVie Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. AbbVie Product
Table 78. AbbVie Recent Development
Table 79. GlaxoSmithKline Corporation Information
Table 80. GlaxoSmithKline Description and Major Businesses
Table 81. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. GlaxoSmithKline Product
Table 83. GlaxoSmithKline Recent Development
Table 84. Pfizer Corporation Information
Table 85. Pfizer Description and Major Businesses
Table 86. Pfizer Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Pfizer Product
Table 88. Pfizer Recent Development
Table 89. Hengrui Pharmaceutical Corporation Information
Table 90. Hengrui Pharmaceutical Description and Major Businesses
Table 91. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. Hengrui Pharmaceutical Product
Table 93. Hengrui Pharmaceutical Recent Development
Table 94. Abbott Laboratories Corporation Information
Table 95. Abbott Laboratories Description and Major Businesses
Table 96. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Abbott Laboratories Product
Table 98. Abbott Laboratories Recent Development
Table 99. Fresenius Kabi Corporation Information
Table 100. Fresenius Kabi Description and Major Businesses
Table 101. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. Fresenius Kabi Product
Table 103. Fresenius Kabi Recent Development
Table 104. Sandoz Corporation Information
Table 105. Sandoz Description and Major Businesses
Table 106. Sandoz Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Sandoz Product
Table 108. Sandoz Recent Development
Table 109. Somerset Therapeutics Corporation Information
Table 110. Somerset Therapeutics Description and Major Businesses
Table 111. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Somerset Therapeutics Product
Table 113. Somerset Therapeutics Recent Development
Table 114. Guike Pharmaceutical Corporation Information
Table 115. Guike Pharmaceutical Description and Major Businesses
Table 116. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Guike Pharmaceutical Product
Table 118. Guike Pharmaceutical Recent Development
Table 119. Shanghai Pharmaceuticals Corporation Information
Table 120. Shanghai Pharmaceuticals Description and Major Businesses
Table 121. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Shanghai Pharmaceuticals Product
Table 123. Shanghai Pharmaceuticals Recent Development
Table 124. Themis Medicare Corporation Information
Table 125. Themis Medicare Description and Major Businesses
Table 126. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 127. Themis Medicare Product
Table 128. Themis Medicare Recent Development
Table 129. Nanjing King-Friend Corporation Information
Table 130. Nanjing King-Friend Description and Major Businesses
Table 131. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 132. Nanjing King-Friend Product
Table 133. Nanjing King-Friend Recent Development
Table 134. Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions (2021-2026) (MT)
Table 135. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share Forecast by Regions (2021-2026)
Table 136. Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 137. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share Forecast by Regions (2021-2026)
Table 138. North America: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 139. North America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Europe: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 141. Europe: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Asia Pacific: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Region (2021-2026) (MT)
Table 143. Asia Pacific: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 144. Latin America: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 145. Latin America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 147. Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 149. Key Challenges
Table 150. Market Risks
Table 151. Main Points Interviewed from Key Neuromuscular Blocking Agent (NMBA) Players
Table 152. Neuromuscular Blocking Agent (NMBA) Customers List
Table 153. Neuromuscular Blocking Agent (NMBA) Distributors List
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
Table 1. Neuromuscular Blocking Agent (NMBA) Market Segments
Table 2. Ranking of Global Top Neuromuscular Blocking Agent (NMBA) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of Depolarizing
Table 5. Major Manufacturers of Non-depolarizing
Table 6. COVID-19 Impact Global Market: (Four Neuromuscular Blocking Agent (NMBA) Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Neuromuscular Blocking Agent (NMBA) Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Neuromuscular Blocking Agent (NMBA) Players to Combat Covid-19 Impact
Table 11. Global Neuromuscular Blocking Agent (NMBA) Market Size Growth Rate by Application 2020-2026 (MT)
Table 12. Global Neuromuscular Blocking Agent (NMBA) Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 13. Global Neuromuscular Blocking Agent (NMBA) Sales by Regions 2015-2020 (MT)
Table 14. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Regions (2015-2020)
Table 15. Global Neuromuscular Blocking Agent (NMBA) Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Neuromuscular Blocking Agent (NMBA) Sales by Manufacturers (2015-2020) (MT)
Table 17. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturers (2015-2020)
Table 18. Global Neuromuscular Blocking Agent (NMBA) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Neuromuscular Blocking Agent (NMBA) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromuscular Blocking Agent (NMBA) as of 2019)
Table 20. Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Neuromuscular Blocking Agent (NMBA) Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Neuromuscular Blocking Agent (NMBA) Price (2015-2020) (USD/MT)
Table 23. Neuromuscular Blocking Agent (NMBA) Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Neuromuscular Blocking Agent (NMBA) Product Type
Table 25. Date of International Manufacturers Enter into Neuromuscular Blocking Agent (NMBA) Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 28. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Type (2015-2020)
Table 29. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Neuromuscular Blocking Agent (NMBA) Revenue Share by Type (2015-2020)
Table 31. Neuromuscular Blocking Agent (NMBA) Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 33. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Application (2015-2020)
Table 34. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 35. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 36. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 38. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 39. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 40. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 41. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 42. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 43. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 44. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 46. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 47. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 48. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 49. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2015-2020) (MT)
Table 51. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 55. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 57. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 58. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 59. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 62. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 63. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 64. Latin America Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 65. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2015-2020) (MT)
Table 67. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2015-2020) (MT)
Table 71. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2015-2020) (MT)
Table 73. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Table 74. AbbVie Corporation Information
Table 75. AbbVie Description and Major Businesses
Table 76. AbbVie Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. AbbVie Product
Table 78. AbbVie Recent Development
Table 79. GlaxoSmithKline Corporation Information
Table 80. GlaxoSmithKline Description and Major Businesses
Table 81. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. GlaxoSmithKline Product
Table 83. GlaxoSmithKline Recent Development
Table 84. Pfizer Corporation Information
Table 85. Pfizer Description and Major Businesses
Table 86. Pfizer Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Pfizer Product
Table 88. Pfizer Recent Development
Table 89. Hengrui Pharmaceutical Corporation Information
Table 90. Hengrui Pharmaceutical Description and Major Businesses
Table 91. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. Hengrui Pharmaceutical Product
Table 93. Hengrui Pharmaceutical Recent Development
Table 94. Abbott Laboratories Corporation Information
Table 95. Abbott Laboratories Description and Major Businesses
Table 96. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Abbott Laboratories Product
Table 98. Abbott Laboratories Recent Development
Table 99. Fresenius Kabi Corporation Information
Table 100. Fresenius Kabi Description and Major Businesses
Table 101. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. Fresenius Kabi Product
Table 103. Fresenius Kabi Recent Development
Table 104. Sandoz Corporation Information
Table 105. Sandoz Description and Major Businesses
Table 106. Sandoz Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Sandoz Product
Table 108. Sandoz Recent Development
Table 109. Somerset Therapeutics Corporation Information
Table 110. Somerset Therapeutics Description and Major Businesses
Table 111. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Somerset Therapeutics Product
Table 113. Somerset Therapeutics Recent Development
Table 114. Guike Pharmaceutical Corporation Information
Table 115. Guike Pharmaceutical Description and Major Businesses
Table 116. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Guike Pharmaceutical Product
Table 118. Guike Pharmaceutical Recent Development
Table 119. Shanghai Pharmaceuticals Corporation Information
Table 120. Shanghai Pharmaceuticals Description and Major Businesses
Table 121. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Shanghai Pharmaceuticals Product
Table 123. Shanghai Pharmaceuticals Recent Development
Table 124. Themis Medicare Corporation Information
Table 125. Themis Medicare Description and Major Businesses
Table 126. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 127. Themis Medicare Product
Table 128. Themis Medicare Recent Development
Table 129. Nanjing King-Friend Corporation Information
Table 130. Nanjing King-Friend Description and Major Businesses
Table 131. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 132. Nanjing King-Friend Product
Table 133. Nanjing King-Friend Recent Development
Table 134. Global Neuromuscular Blocking Agent (NMBA) Sales Forecast by Regions (2021-2026) (MT)
Table 135. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share Forecast by Regions (2021-2026)
Table 136. Global Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 137. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share Forecast by Regions (2021-2026)
Table 138. North America: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 139. North America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Europe: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 141. Europe: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Asia Pacific: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Region (2021-2026) (MT)
Table 143. Asia Pacific: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 144. Latin America: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 145. Latin America: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Sales Forecast by Country (2021-2026) (MT)
Table 147. Middle East and Africa: Neuromuscular Blocking Agent (NMBA) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 148. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 149. Key Challenges
Table 150. Market Risks
Table 151. Main Points Interviewed from Key Neuromuscular Blocking Agent (NMBA) Players
Table 152. Neuromuscular Blocking Agent (NMBA) Customers List
Table 153. Neuromuscular Blocking Agent (NMBA) Distributors List
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Neuromuscular Blocking Agent (NMBA) Product Picture
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2020 & 2026
Figure 3. Depolarizing Product Picture
Figure 4. Non-depolarizing Product Picture
Figure 5. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Others
Figure 10. Neuromuscular Blocking Agent (NMBA) Report Years Considered
Figure 11. Global Neuromuscular Blocking Agent (NMBA) Market Size 2015-2026 (US$ Million)
Figure 12. Global Neuromuscular Blocking Agent (NMBA) Sales 2015-2026 (MT)
Figure 13. Global Neuromuscular Blocking Agent (NMBA) Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2015-2020)
Figure 15. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region in 2019
Figure 16. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2015-2020)
Figure 17. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region in 2019
Figure 18. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Neuromuscular Blocking Agent (NMBA) Revenue in 2019
Figure 20. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Figure 22. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2019
Figure 23. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2015-2020)
Figure 24. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type in 2019
Figure 25. Global Neuromuscular Blocking Agent (NMBA) Market Share by Price Range (2015-2020)
Figure 26. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Figure 27. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2019
Figure 28. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2015-2020)
Figure 29. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application in 2019
Figure 30. North America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 31. North America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 33. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 34. U.S. Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 35. U.S. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 37. Canada Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 39. North America Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 40. Europe Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 41. Europe Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 43. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 44. Germany Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 45. Germany Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 47. France Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 49. U.K. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 51. Italy Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 53. Russia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 55. Europe Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 56. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 57. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region in 2019
Figure 59. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region in 2019
Figure 60. China Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 61. China Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 63. Japan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 65. South Korea Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 67. India Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 69. Australia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 71. Taiwan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 73. Indonesia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 75. Thailand Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 77. Malaysia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 79. Philippines Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 81. Vietnam Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 83. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 84. Latin America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 85. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 87. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 88. Mexico Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 89. Mexico Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 91. Brazil Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 93. Argentina Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 95. Latin America Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 96. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 97. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 100. Turkey Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 101. Turkey Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 103. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 105. U.A.E Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 107. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 108. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Hengrui Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Fresenius Kabi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Somerset Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Guike Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Shanghai Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Themis Medicare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Nanjing King-Friend Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. North America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 121. North America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Europe Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 123. Europe Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 125. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Latin America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 127. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 129. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Porter's Five Forces Analysis
Figure 131. Channels of Distribution
Figure 132. Distributors Profiles
Figure 133. Bottom-up and Top-down Approaches for This Report
Figure 134. Data Triangulation
Figure 135. Key Executives Interviewed
Figure 1. Neuromuscular Blocking Agent (NMBA) Product Picture
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2020 & 2026
Figure 3. Depolarizing Product Picture
Figure 4. Non-depolarizing Product Picture
Figure 5. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Others
Figure 10. Neuromuscular Blocking Agent (NMBA) Report Years Considered
Figure 11. Global Neuromuscular Blocking Agent (NMBA) Market Size 2015-2026 (US$ Million)
Figure 12. Global Neuromuscular Blocking Agent (NMBA) Sales 2015-2026 (MT)
Figure 13. Global Neuromuscular Blocking Agent (NMBA) Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2015-2020)
Figure 15. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region in 2019
Figure 16. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2015-2020)
Figure 17. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region in 2019
Figure 18. Global Neuromuscular Blocking Agent (NMBA) Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Neuromuscular Blocking Agent (NMBA) Revenue in 2019
Figure 20. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2015-2020)
Figure 22. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2019
Figure 23. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2015-2020)
Figure 24. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type in 2019
Figure 25. Global Neuromuscular Blocking Agent (NMBA) Market Share by Price Range (2015-2020)
Figure 26. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2015-2020)
Figure 27. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2019
Figure 28. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2015-2020)
Figure 29. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application in 2019
Figure 30. North America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 31. North America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 33. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 34. U.S. Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 35. U.S. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 37. Canada Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 39. North America Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 40. Europe Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 41. Europe Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 43. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 44. Germany Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 45. Germany Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 47. France Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 49. U.K. Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 51. Italy Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 53. Russia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 55. Europe Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 56. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 57. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region in 2019
Figure 59. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region in 2019
Figure 60. China Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 61. China Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 63. Japan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 65. South Korea Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 67. India Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 69. Australia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 71. Taiwan Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 73. Indonesia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 75. Thailand Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 77. Malaysia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 79. Philippines Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 81. Vietnam Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 83. Asia Pacific Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 84. Latin America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 85. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 87. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 88. Mexico Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 89. Mexico Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 91. Brazil Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 93. Argentina Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 95. Latin America Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 96. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Growth Rate 2015-2020 (MT)
Figure 97. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country in 2019
Figure 100. Turkey Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 101. Turkey Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 103. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Neuromuscular Blocking Agent (NMBA) Sales Growth Rate (2015-2020) (MT)
Figure 105. U.A.E Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Share by Type in 2019
Figure 107. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Market Share by Application in 2019
Figure 108. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Hengrui Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Fresenius Kabi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Somerset Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Guike Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Shanghai Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Themis Medicare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Nanjing King-Friend Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. North America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 121. North America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Europe Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 123. Europe Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Asia Pacific Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 125. Asia Pacific Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Latin America Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 127. Latin America Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Sales Growth Rate Forecast (2021-2026) (MT)
Figure 129. Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Porter's Five Forces Analysis
Figure 131. Channels of Distribution
Figure 132. Distributors Profiles
Figure 133. Bottom-up and Top-down Approaches for This Report
Figure 134. Data Triangulation
Figure 135. Key Executives Interviewed
